1 / 3

Dr David Greene R3 Stem Cell Stem Cell Treatment for Brittle Bones

According to Dr David Greene, R3 stem cell osteogenesis imperfecta, also known as brittle bone disease, results in weak, easily broken bones during fetal development (osteoblasts). The essential component of bones and skin is collagen; therefore, a mutation causes aberrant or insufficient collagen, resulting in decreased bone mass and strength. For more information, visit our website.<br>

R310
Télécharger la présentation

Dr David Greene R3 Stem Cell Stem Cell Treatment for Brittle Bones

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DR DAVID GREENE R3 STEM CELL Stem Cell Treatment for Brittle Bones In response to a genetic mutation in the genes coding for collagen produced by bone-forming cells, osteogenesis imperfecta, also familiar as brittle bone disease, presents as weak, easily broken bones before birth (osteoblasts). www.r3stemcell.com

  2. STEM CELLS AS A THERAPEUTIC TREATMENT In tissues of mesenchymal/stromal origin, such as bone marrow, human mesenchymal stem cells (MSCs) are present. Other organs have also been identified at different gestation periods to produce stem cells resembling bone marrow MSCs. Human fetal MSCs (hfMSCs), also known as fetal MSCs, have various advantages over adult MSCs, including faster cell division, better specialization capabilities, and greater capacity for tissue repair. In addition, MSCs can be separated from healthy donors, multiplied in vitro, and frozen at extremely low temperatures. www.r3stemcell.com

  3. THE FUTURE OF PERSONALIZED MEDICINE The capacity to fix genetic mutations using genetic scissors to delete particular portions of DNA is another cutting-edge method for treating osteogenesis imperfecta. Somatic cells from patients are isolated from their urine, rejuvenated in vitro to become pluripotent, genetically modified to remove the mutation- causing osteogenesis imperfecta, and differentiated into iMSCs before being transplanted. This allows for the development of personalized stem cell therapy. Such a strategy exemplifies the benefits of standardizing care. www.r3stemcell.com

More Related